BRAF and colorectal carcinoma: According to the guideline by the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology on biomarker evaluation in colorectal carcinoma, evaluation of mutation in BRAF and KRAS genes is recommended (4).